136 related articles for article (PubMed ID: 30585844)
1. Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors.
Gelpi M; Afzal S; Fuchs A; Lundgren J; Knudsen AD; Drivsholm N; Mocroft A; Lebech AM; Lindegaard B; Kühl JT; Sigvardsen PE; Køber L; Nordestgaard BG; Kofoed KF; Nielsen SD
AIDS; 2019 Mar; 33(4):675-683. PubMed ID: 30585844
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure.
Gelpi M; Knudsen AD; Larsen KB; Mocroft A; Lebech AM; Lindegaard B; Lundgren J; Kofoed KF; Nielsen SD;
BMC Infect Dis; 2019 Aug; 19(1):708. PubMed ID: 31399063
[TBL] [Abstract][Full Text] [Related]
3. Pericardial Adipose Tissue Volume Is Independently Associated With Human Immunodeficiency Virus Status and Prior Use of Stavudine, Didanosine, or Indinavir.
Knudsen AD; Krebs-Demmer L; Bjørge NID; Elming MB; Gelpi M; Sigvardsen PE; Lebech AM; Fuchs A; Kühl JT; Køber L; Lundgren J; Nordestgaard BG; Kofoed KF; Nielsen SD
J Infect Dis; 2020 Jun; 222(1):54-61. PubMed ID: 32027374
[TBL] [Abstract][Full Text] [Related]
4. Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study.
Gelpi M; Afzal S; Lundgren J; Ronit A; Roen A; Mocroft A; Gerstoft J; Lebech AM; Lindegaard B; Kofoed KF; Nordestgaard BG; Nielsen SD
Clin Infect Dis; 2018 Aug; 67(4):579-586. PubMed ID: 29471519
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance in people living with HIV is associated with exposure to thymidine analogues and/or didanosine and prior immunodeficiency.
Høgh J; Hove-Skovsgaard M; Gelpi M; Jensen AMR; Gerstoft J; Benfield T; Storgaard H; Nielsen SD
BMC Infect Dis; 2022 May; 22(1):503. PubMed ID: 35643429
[TBL] [Abstract][Full Text] [Related]
6. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
Young B; Weidle PJ; Baker RK; Armon C; Wood KC; Moorman AC; Holmberg SD;
AIDS Patient Care STDS; 2006 Apr; 20(4):238-44. PubMed ID: 16623622
[TBL] [Abstract][Full Text] [Related]
7. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
[TBL] [Abstract][Full Text] [Related]
8. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
Ruxrungtham K; Kroon ED; Ungsedhapand C; Teeratakulpisarn S; Ubolyam S; Buranapraditkun S; van Leeuwen R; Weverling GJ; Kunanusont C; Lange JM; Cooper DA; Phanuphak P
AIDS; 2000 Jul; 14(10):1375-82. PubMed ID: 10930152
[TBL] [Abstract][Full Text] [Related]
9. Association of Changes in Abdominal Fat Quantity and Quality With Incident Cardiovascular Disease Risk Factors.
Lee JJ; Pedley A; Hoffmann U; Massaro JM; Fox CS
J Am Coll Cardiol; 2016 Oct; 68(14):1509-21. PubMed ID: 27687192
[TBL] [Abstract][Full Text] [Related]
10. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
García-Benayas T; Rendón AL; Rodríguez-Novóa S; Barrios A; Maida I; Blanco F; Barreiro P; Rivas P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Apr; 22(4):333-7. PubMed ID: 16623636
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic insufficiency in patients with HIV infection: role of didanosine questioned.
Martin TC; Scourfield A; Rockwood N; Martin NK; Patel N; Nelson M; Gazzard BG
HIV Med; 2013 Mar; 14(3):161-6. PubMed ID: 22994793
[TBL] [Abstract][Full Text] [Related]
12. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Kelleher T; Cross A; Dunkle L
Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
[TBL] [Abstract][Full Text] [Related]
13. Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV.
Srinivasa S; Fitch KV; Torriani M; Zanni MV; Defilippi C; Christenson R; Maehler P; Looby SE; Lo J; Grinspoon SK
AIDS; 2019 Feb; 33(2):229-236. PubMed ID: 30325779
[TBL] [Abstract][Full Text] [Related]
14. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors.
Abraham TM; Pedley A; Massaro JM; Hoffmann U; Fox CS
Circulation; 2015 Oct; 132(17):1639-47. PubMed ID: 26294660
[TBL] [Abstract][Full Text] [Related]
15. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.
Suárez-Zarracina T; Valle-Garay E; Collazos J; Montes AH; Cárcaba V; Carton JA; Asensi V
J Viral Hepat; 2012 Oct; 19(10):685-93. PubMed ID: 22967099
[TBL] [Abstract][Full Text] [Related]
16. Improved gastrointestinal tolerance and palatability of didanosine in adults by the use of pediatric power formulation.
Dodge RT; Shipp KW; Miralles GD
J Assoc Nurses AIDS Care; 1998; 9(5):27-31. PubMed ID: 9742478
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
Barreiro P; de Mendoza C; Camino N; García-Benayas T; Blanco F; Núñez M; González-Lahoz J; Soriano V
HIV Clin Trials; 2003; 4(6):361-71. PubMed ID: 14628279
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.
Schouten JN; Van der Ende ME; Koëter T; Rossing HH; Komuta M; Verheij J; van der Valk M; Hansen BE; Janssen HL
Aliment Pharmacol Ther; 2012 Nov; 36(9):875-85. PubMed ID: 22971050
[TBL] [Abstract][Full Text] [Related]
20. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
